Skip to main content
Preview

Research from Friday’s close · next update overnight after Monday’s close

Radar
BSX

BSX Research brief

Boston Scientific

Adjusted close as of 2026-10-30
$41.98(−1.66%)

Sagehood’s view on BSX

Boston Scientific · Research 2026-10-30 · Accepted

Research score

40Bearish50 is balancedScore unchanged since 2026-10-29 at 40; view unchanged at Bearish. Compare the two recordsConfidence 55 · It is not a calibrated probability of investment success.Confidence across the 100 names in this research run: 45 to 70, median 55.
How to read this score

In Sagehood30 · book 2026-10-30

Dated research brief

WhyBoston Scientific's bearish case is driven by a broken trend, since the 1-year channel slopes −64.2% per year and price sits 25.7% below 200-day average. The unresolved risk is that 13.5% revenue growth and a 19.8% operating margin keep the franchise intact.
What argues against this viewThe strongest case against the bearish view is the operating quality. Trailing-twelve-month revenue of $20,996 million grew 13.5% against the 4.6% sector median, and operating margin was 19.8% versus 17.1%.
Break conditionFrom the financial specialist: A later reading showing trailing-twelve-month revenue growth below the 4.6% sector revenue-growth median would break the growth claim.Tests that specialist’s reading, not this page’s whole Bearish view.

Sagehood does not check this condition automatically. See research limitations below.

Valuation range

Close vs. model fair value · discounted cash flow

Bear
$21.40
Base
$58.60
Bull
$113.50

Base case +40% vs. the 2026-10-30 close, on fundamentals to 2026-06-30. Peer-implied median $66.04 from 3 peer-median multiples. Estimates from this research’s valuation model, not a price target.

Against peers

Health Care
MultipleBSXGroup medianPercentile
P/E (TTM)17.00×31.97×25th
P/S2.99×3.02×50th
P/B2.52×3.96×50th
FCF yield5.78%5.61%50th
Score details & research limitations9 unavailable fields
Conditions Sagehood can check on its ownNot available in this run. A written break condition is not an automated check; this run does not provide a source-linked rule Sagehood can verify on its own.

Where the break condition comes from: Sagehood research took this condition from the financial specialist. It tests that specialist’s own reading, so it does not say everything that would change this page’s Bearish view.

How to read this research

The score expresses the published research view. 50 is balanced.

Bullish, Neutral or Bearish beside the score is the direction of that view, set by the research from the score: 65 and above is Bullish, 45 to 64 Neutral, 44 and below Bearish.

Confidence is how well the evidence supports this view, not which way it points: Sagehood research is asked to keep it no higher than its most confident specialist, and lower when the specialists disagree or much of the evidence is weak. It is not a calibrated probability of investment success.

Source verification checks the identity and origin of evidence. It does not prove that a claim is correct or that an investment will succeed.

Valuation estimates depend on their inputs and assumptions. They are not guaranteed future prices.

Retrospective research looks back at an earlier period. It is not a verified record of a decision made then using only information available then.

Unavailable is not zero. Read the adjacent reason: information may be missing, unverified or deliberately withheld.

How Sagehood works

The session this view is fixed to

Close$41.98 on 2026-10-30, as the research recorded it
Change on the day−1.66%
First eligible market session2026-11-02

Recorded score context

Specialist source coverage8 of 10 specialists have a verified source on this run. 2 do not.
Score reconciliationThe 8 specialist contributions shown add up to the weighted starting point this score was built from.
Change since the last accepted run40 on 2026-10-29 → 40 on 2026-10-30 (0 points). This is simple arithmetic between the two published scores, not an explanation of the change.
The run this is compared withResearch of 2026-10-29

Not in this run: Run-specific score definition, Confidence band, Horizon, Why the score changed, Today's unexplained move and Blockers.

What this was built from

Filing cited in the evidenceNot recorded on this card. The newest filing on record is under Key financials, and recent filings are listed under SEC filings.
Peer set6 names in Health Care: BMY, MDT, MRK, MRNA, PFE, VTRS. How they were chosen is under “Valuation & peers”. The valuation range shows the peer-implied median from 3 peer-median multiples.

Not in this run: Company profile date and Standing disclosure.

Not available in this run

9 fields are unavailable. Each is identified with its reason above; missing information is not zero or a negative research signal.

Price context

· adjusted close $41.98

−5.0% from 2026-06-25

Recent price-basis check: 2026-10-02 to 2026-10-30 (20 sessions). Economic comparability outside this window remains unchecked.

BSX adjusted close
Adjusted price · USD · viewing 2026-06-25 to 2026-10-30

Selected 2026-10-30. BSX adjusted close. Continuous series. $41.98 US dollars.

90 daily adjusted-price observations through 2026-10-30, ending at the 2026-10-30 research date. The final point is a dated final close. Shown for context, not point-in-time research evidence: the research used the prices recorded with it.

Use the arrow keys on the chart to step through observations.

Published score history

2026-07-23 to 2026-10-30 · 37 publications

Each point is a verified published score. The line breaks where the research method changed (4 methods, numbered in the order they were first used), so scores are not joined across methods. Hollow points were published after their decision window (retrospective).

Every published score and confidence
Research dateScoreViewConfidenceMethod
2026-10-3040Bearish55Method 4
2026-10-2940Bearish55Method 4
2026-10-2844Bearish49Method 4
2026-10-2745Neutral55Method 4
2026-10-2650Neutral55Method 4
2026-10-2347Neutral55Method 4
2026-10-2250Neutral48Method 4
2026-10-2142Bearish48Method 4
2026-10-1644Bearish45Method 4
2026-10-0939Bearish58Method 4
2026-10-0734Bearish55Method 4
2026-10-0236Bearish60Method 4
2026-10-0138Bearish60Method 4
2026-09-3046Neutral60Method 4
2026-09-2945Neutral55Method 4
2026-09-2845Neutral70Method 4
2026-09-2542Bearish55Method 4
2026-09-24 · retrospective43Bearish55Method 4
2026-09-2342Bearish55Method 4
2026-09-1844Bearish65Method 4
2026-09-16 · retrospective38Bearish55Method 4
2026-09-09 · retrospective41Bearish58Method 4
2026-09-0444Bearish60Method 4
2026-09-01 · retrospective50Neutral60Method 4
2026-08-31 · retrospective50Neutral63Method 3
2026-08-2851Neutral63Method 3
2026-08-26 · retrospective51Neutral62Method 3
2026-08-24 · retrospective51Neutral62Method 3
2026-08-20 · retrospective50Neutral62Method 3
2026-08-19 · retrospective47Neutral72Method 3
2026-08-1448Neutral62Method 2
2026-08-1351Neutral62Method 1
2026-08-0751Neutral62Method 1
2026-08-0651Neutral62Method 1
2026-08-0452Neutral62Method 1
2026-07-3148Neutral69Method 1
2026-07-2347Neutral48Method 1

Specialists

8 of 10 published specialist analyses are available.

Each specialist’s view is shown as the published research recorded it; supporting detail appears only when it was recorded with that same view.

2 unavailable

BSX research

Financial specialist

Showing Financial specialist result.

Financial specialist

Evaluated for this session

Bullish

Boston Scientific is a high-quality medtech compounder. Trailing-twelve-month revenue of $20,996 million grew 13.5%, above the 4.6% sector revenue-growth median, with operating margin of 19.8% and free cash flow of $3,625 million.

Full analyst note

What the specialist sees

Evidence: trailing-twelve-month revenue of $20,996 million grew 13.5% versus the 4.6% sector revenue-growth median, operating margin was 19.8% against the 17.1% sector operating-margin median, trailing-twelve-month free cash flow was $3,625 million with free-cash-flow conversion of 0.99, and net debt to EBITDA was 0.21 with interest coverage of 11.44.

Why it matters now

Above-median revenue growth and operating margin with near-full cash conversion and a lightly levered balance sheet indicate a durable medtech franchise, though quarterly growth decelerated from 20.3% to 7.5% and the 88-day gap since the last report leaves the current trajectory unconfirmed.

What could change the view

Countercase: The read would be wrong if the deceleration from 20.3% to 7.5% quarterly growth reflects competitive share loss rather than a tough comparison, and the 88-day-old report means the next filing could reset the trajectory. Falsifier: A later reading showing trailing-twelve-month revenue growth below the 4.6% sector revenue-growth median would break the growth claim.

Specialist score details
Specialist score
72
Evidence confidence
60
Base weight for this role
0.13
Base weight × confidence
7.80
Weight in the score (the chip's weight)
0.14
Weighted contribution
10.34
Business driver
Trailing-twelve-month revenue of $20,996 million grew 13.5% versus the 4.6% sector revenue-growth median, operating margin was 19.8% against the 17.1% sector operating-margin median, trailing-twelve-month free cash flow was $3,625 million with free-cash-flow conversion of 0.99, and net debt to EBITDA was 0.21 with interest coverage of 11.44.
Mechanism
Above-median revenue growth and operating margin with near-full cash conversion and a lightly levered balance sheet indicate a durable medtech franchise, though quarterly growth decelerated from 20.3% to 7.5% and the 88-day gap since the last report leaves the current trajectory unconfirmed.
Countercase
The read would be wrong if the deceleration from 20.3% to 7.5% quarterly growth reflects competitive share loss rather than a tough comparison, and the 88-day-old report means the next filing could reset the trajectory.
Contributions & coverage details

Specialist contributions

Each specialist’s recorded numbers, in the usual specialist order, as recorded: nothing is re-ranked or recalculated. Weights and contributions show two decimals; hover for the exact value.

Financial specialist

Bullish

Score
72
Evidence confidence
60
Weight in the score
0.14
Weighted contribution
10.34

Risk specialist

Bearish

Score
28
Evidence confidence
62
Weight in the score
0.09
Weighted contribution
2.56

Sector specialist

Bearish

Score
38
Evidence confidence
55
Weight in the score
0.10
Weighted contribution
3.85

SEC filings specialist

Neutral

Score
45
Evidence confidence
55
Weight in the score
0.03
Weighted contribution
1.37

News specialist

Bearish

Score
38
Evidence confidence
60
Weight in the score
0.12
Weighted contribution
4.62

Price-trend specialist

Bearish

Score
25
Evidence confidence
65
Weight in the score
0.24
Weighted contribution
5.98

Valuation specialist

Neutral

Score
55
Evidence confidence
65
Weight in the score
0.19
Weighted contribution
10.53

Economy specialist

Neutral

Score
54
Evidence confidence
55
Weight in the score
0.08
Weighted contribution
4.37

Published specialist analyses unavailable: Geopolitics specialist, Social-media specialist. No specialist result is inferred.

  • Geopolitics specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.
  • Social-media specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.

How this insight was formed

Each specialist view shown here is checked against the published research files. Sagehood research combined those views into the one Research Score above.

Evidence & method

Inspect the reasoning, source records and valuation behind this dated view.

Sagehood research reasoningSpecialist reasoning, selected statements and filing context
Accepted publication2026-10-30 researchNext eligible session 2026-11-02point-in-time

BSX: Sagehood research reasoning

Accepted research score

40

Bearish50 is balanced
Lead specialist in the research decision:

Financial specialist

Bullish

Specialist score 72Evidence confidence 60
What the specialist sees

Trailing-twelve-month revenue of $20,996 million grew 13.5% versus the 4.6% sector revenue-growth median, operating margin was 19.8% against the 17.1% sector operating-margin median, trailing-twelve-month free cash flow was $3,625 million with free-cash-flow conversion of 0.99, and net debt to EBITDA was 0.21 with interest coverage of 11.44.

Why it matters

Above-median revenue growth and operating margin with near-full cash conversion and a lightly levered balance sheet indicate a durable medtech franchise, though quarterly growth decelerated from 20.3% to 7.5% and the 88-day gap since the last report leaves the current trajectory unconfirmed.

What argues against it

The read would be wrong if the deceleration from 20.3% to 7.5% quarterly growth reflects competitive share loss rather than a tough comparison, and the 88-day-old report means the next filing could reset the trajectory.

This specialist’s break condition: A later reading showing trailing-twelve-month revenue growth below the 4.6% sector revenue-growth median would break the growth claim.

How the score was formed

The specialists’ weighted starting point was 43.62. Sagehood research’s adjustment was −3.62. 40 on 2026-10-29 → 40 on 2026-10-30 (0 points). This is simple arithmetic between the two published scores, not an explanation of the change.

Evidence Sagehood research weighed

These selected claims are evidence Sagehood research weighed, not a reconstruction of the numeric adjustment.

Claims as this research published them. Sagehood confirms each claim and its support were published together with this research. That is not an independent check, and it does not prove the claim is accurate or predict future performance.

  1. Financial specialist

    Same statement as under “What the specialist sees” above.

  2. Price-trend specialist

    The 1-year channel slope is −64.2% per year with trend-channel position +1.29 standard deviations, and price is −25.7% below 200-day average with a death cross 262 days old. 14-week RSI is 34.3 and 14-day RSI 38.8, while the nearest support at $41.58 is 1.0% below the close and the 52-week low is $41.58.

  3. News specialist

    material-news net tone was −0.15 with bad-news days followed by underperformance 6 against good-news days followed by outperformance 1, and the 2026-10-28 earnings items showed one-day return relative to SPY of −6.18 and three-session return after the news of −6.84, while bad-news days followed by outperformance was 7.

Sagehood research decision

The investment case, main risk and break condition are the ones shown under Sagehood’s view at the top of this page.

Recorded break condition
Break condition as kept in the decision trail

A later reading showing TTM revenue growth below the 4.6% sector revenue-growth median would break the growth claim.

Evidence & sourcesClaim-support availability, filing-context links and research method

BSX: This run has no checked links from its claims to their evidence. The specialists’ writing is shown as recorded, and no missing evidence is filled in.

Accepted research

Research dated 2026-10-30.

How this research was made

This research is AI-generated and is not investment advice.

Research date
2026-10-30
Valuation & peersInput limits notedFair-value cells, peer multiples and the inputs behind the range

Valuation the research computed

Against the 2026-10-30 close of $41.98 (recorded)

Fundamentals reference date: 2026-06-30.

Fair value by discounted cash flow, at the cells this run nominated.

Bear
$21.40−49% vs close
Base
$58.60+40% vs close
Bull
$113.50+170% vs close

Implied by the median of 3 peer-median multiples: $66.04 (+57.3% vs close)

Peers: the 6 Liquid 100 names in Health Care that this run priced. Companies outside the Liquid 100 are not in the set.

The names: BMY, MDT, MRK, MRNA, PFE, VTRS.

Multiples against the peer group

Health Care · 6 companies in the group

  • Price to earnings (trailing twelve months)17.00×

    Peer median 31.97× · middle half 21.30× to 60.02× · 25th percentile of the group

  • Price to sales2.99×

    Peer median 3.02× · middle half 2.61× to 4.99× · 50th percentile of the group

  • Price to book2.52×

    Peer median 3.96× · middle half 2.15× to 7.97× · 50th percentile of the group

  • Free cash flow yield5.78%

    Peer median 5.61% · middle half 4.5% to 7.01% · 50th percentile of the group

This run declares Enterprise value to EBITDA and computes no value for it, for this company or for its peer group.

Evidence limits: 10 valuation inputs required conservative handling: another valuation input required conservative handling; depreciation and amortization were available but not used because this version does not compute an EV/EBITDA multiple; debt coverage was incomplete.

Includes the currently displayed specialist or comparison, not every specialist. Dates and limitations remain attached.

Sagehood research is for general information. It is not individualized investment advice or a recommendation to buy or sell any security.

Boston Scientific (BSX) research | Sagehood